UCL has made dementia a priority
Dementia is the greatest scientific, medical and socio-economic challenge of our times and affects more than 46 million people worldwide. As populations age, dementia is inevitably going to become more common with devastating personal, social and economic implications.
UCL can lay claim to world-leading expertise across the spectrum of research, from genetics to evidence based treatments and support for patients and carers. We have both the ambition and ability to make a difference and meet the challenge of this most pressing of global public health problems.
The UK Dementia Research Institute is a joint investment into dementia research led by the Medical Research Council alongside founding charity partners Alzheimer’s Society and Alzheimer’s Research UK. The Institute will be catalytic in the UK’s research efforts to diagnose, treat, care for and prevent dementias, a group of neurodegenerative disorders which include Alzheimer’s, Parkinson’s, Huntington’s disease and vascular dementia. The hub of the institute activity and operational headquarters is based at UCL.
One in three cases of dementia could potentially be prevented if brain health is improved throughout life by targeting nine risk factors, including continuing education in early life, reducing hearing loss in mid-life, and reducing smoking in later life.
Published: Jul 20, 2017 10:17:08 AM
A team led by Professor Michael Hanna, Director of the UCL Institute of Neurology, has won a £28,850,000 infrastructure award from the Higher Education Funding Council for England (HEFCE) to support the improvement of UCL’s research facilities, which will enable UCL to deliver on its aim to create the world’s leading translational neuroscience environment.
Published: Jul 10, 2017 4:04:32 PM